Add To Watchlist
Share URL
About The Company
CEO
Mr. Magnus O. Corfitzen
Market Cap
563.70 Million SEK
Sector
Healthcare
Website
https://www.ascelia.comDescription
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden.
Read More
Overview
Value
5
Growth
2
Health
49
Management
55
Analyst Opinion
60
Total
34
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Has a low level of debt
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Income is not covering expenditure and investment
- Earnings are negative
- There is a history of diluting shareholders
- No margin of safety at their current market price
- Poor earnings and cashflow growth 0
Market Peers
ACE.ST
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-67.10%
Revenue Growth (5 Year Average)
N/A
Ratings Consensus
Neutral
Share Buybacks
-66.79%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
5
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 6.3 SEK ✘
Current Price: 14.3 SEK
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-25.81%
PE/Earnings Growth
N/A
Price/Book
2.17x
Growth
Growth Score
2
- ✔ Revenue growth has improved this yeara
- ✔ Earnings growth has improved this year
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of -0.01% is lower than the market average (14.48%)
- ✘ 5 Year Average Free Cashflow growth of -20.04% is lower than the market average (12.35%)
Revenue Growth
N/A
Earnings Growth
-0.01%
Cashflow Growth
-20.04%
Health
Health Score
49
Altman Z Score
N/A
Piostroski Score
N/A
Debt/Equity
0.01x
Current Assets/Liabilities
10.94x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
0.01x
Management
Management Score
55
Average Buybacks/Dilution
-66.79%
Recent Buybacks/Dilution
-66.76%
5 Year Price Volitility
32.80%
Return On Assets
-12.55%
Return On Capital Employed
-36.10%
Return On Equity
-13.60%
Return On Free Cashflow
48.71%
Return On Investments
N/A
Analysts
Analyst Opinion
60
- ✔ Ratings consensus is Neutral
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Ascelia Pharma AB (publ)
Currency
SEK
Beta
0.949332
Vol Avg
115646
Ceo
Mr. Magnus O. Corfitzen
Cik
Cusip
Exchange
Stockholm Stock Exchange
Full Time Employees
21
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2019-03-13
Address
Hyllie Boulevard 34
City
Malmö
State
Country
SE
Zip
215 32
Phone
46 735 179 118
All financial data provided by FMP